Last updated: February 23, 2026
What is the drug associated with NDC 00169-4303?
The National Drug Code (NDC) 00169-4303 corresponds to Sovaldi (sofosbuvir), a direct-acting antiviral medication used for treating hepatitis C virus (HCV) infection. Approved by the FDA in 2013, Sovaldi revolutionized HCV treatment, offering higher cure rates with shorter therapy durations.
Market Overview
Market Size and Penetration
Sovaldi's launch in 2013 signaled a significant shift in hepatitis C management. The global hepatitis C drug market was valued at approximately USD 4.66 billion in 2021 and projected to reach USD 4.90 billion by 2025, with Sovaldi constituting a substantial share during early years due to its novelty and efficacy.
Key Market Drivers
- Rising prevalence of hepatitis C globally, affecting an estimated 58 million people worldwide [1].
- Advances in direct-acting antiviral (DAA) therapies, making treatment more effective and tolerable.
- Preferential reimbursement policies in high-income countries, despite high drug costs.
- Patent exclusivity duration, affecting generic entry timelines.
Competitive Landscape
Sovaldi faces competition from other DAAs, such as Harvoni (ledipasvir/sofosbuvir), Epclusa (sofosbuvir/velpatasvir), and Gilead's newer formulations. The competition impacts pricing pressures and market share dynamics.
| Drug |
Year of FDA Approval |
Price at Launch (USD for 12-week course) |
Market Segment Notes |
| Sovaldi |
2013 |
$84,000 |
First-in-class PDV; high initial price led to reimbursement disputes |
| Harvoni |
2014 |
$94,500 |
Combination therapy, broader genotype coverage |
| Epclusa |
2016 |
$74,760 |
Pan-genotypic, lower cost alternative |
Price Trends
Initial Pricing and Reimbursement
At launch, Sovaldi was priced at approximately USD 84,000 per 12-week course, equating to roughly USD 1,000 per pill. This pricing sparked controversy due to high costs versus manufacturing expenses, leading to negotiations with payers and government agencies.
Price Decline Over Time
Prices of Sovaldi declined due to:
- Entry of generics in some markets, especially India, where manufacturing costs are lower.
- Competition from other DAAs.
- Negotiation and formulary inclusion, which pressured Gilead Sciences to offer discounts.
In 2018, the average wholesale price (AWP) for Sovaldi decreased by 20-30% in the US, and some payers obtained significant discounts through rebate agreements.
Price projections (2023-2030)
| Year |
Estimated Price (USD) for 12-week course |
Key Factors |
| 2023 |
$54,000 - $65,000 |
Patent protections limit generics; negotiations continue |
| 2025 |
$40,000 - $50,000 |
Potential generic entry in emerging markets, patent challenges in some jurisdictions |
| 2030 |
$20,000 - $30,000 |
Broader generic manufacturing, patent expirations in key markets |
The decline depends heavily on patent litigation outcomes, international patent protections, and market access policies.
Patent and Regulatory Considerations
Gilead's patent on sofosbuvir in the US extends into the late 2020s, with some patent challenges ongoing. Patent expirations in certain markets may lower prices and accelerate generic competition.
The FDA approved combination formulations (e.g., Harvoni, Epclusa) have extended patent protections or exclusivity periods, influencing Sovaldi's market share and pricing.
Regulatory and Market Risks
- Patent challenges could lead to generics, reducing prices.
- Pricing regulations in major markets (e.g., EU, US) may impose price caps.
- Global hepatitis C prevalence reduction initiatives may affect demand.
Market Opportunity and Strategic Outlook
Gilead's focus shifts toward generic markets and expanding indications for existing DAAs. Entry into broader markets and licensing agreements may alter pricing and revenue over the next decade.
Shift toward pan-genotypic regimens and combination therapies could reduce Sovaldi's standalone market share.
Key Takeaways
- The US launch price of Sovaldi was USD 84,000 for a 12-week course.
- Prices are expected to decline to USD 20,000-30,000 by 2030 due to patent expirations and generics.
- Market competition and regulatory developments significantly influence prices.
- The total hepatitis C market is projected to grow modestly, with declining treatment costs facilitating broader access.
- Gilead's future revenue depends on patent litigation, generic approvals, and evolving treatment protocols.
FAQs
1. How do patent protections influence Sovaldi’s pricing?
Patent protections prevent generic manufacturing, maintaining high prices. Loss of patent exclusivity typically results in price reductions due to generic competition.
2. What factors could accelerate price declines?
Patent expiry, legal challenges, regulatory approvals for generics, and international price controls.
3. How does the US marketplace differ from emerging markets in pricing?
The US prices are highest due to less government regulation and higher reimbursement rates. Emerging markets see lower prices due to local manufacturing, patents, and market policies.
4. Will new hepatitis C therapies replace Sovaldi?
Newer pan-genotypic drugs with shorter regimens and fewer side effects are replacing older therapies, including Sovaldi, especially where patent protections expire.
5. What impact might biosimilars or generics have on the market?
They will pressure prices downward significantly, especially in markets where patent challenges succeed or patent protections expire.
References
- World Health Organization. (2022). Hepatitis C. WHO. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
